The study, published in PLOS Genetics on 20 December, adds to growing evidence that particular genes are involved in chronic pain and highlights this pathway as a potential target for more effective pain relief treatments for patients.
The collaborative study between King's, Pfizer Ltd and the Beijing Genomics Institute (BGI), used a new method to study and compare DNA, called 'exome sequencing', to identify genetic variations relating to pain sensitivity.